DNA Test Could Spare 6,600 Breast Cancer Patients From Unnecessary Chemotherapy
New genetic testing could spare 6,600 UK breast cancer patients annually from unnecessary chemotherapy while maintaining equivalent survival rates. International…
Editor's Top Picks
New Blood Tests and Stool Screens Join Colonoscopy as Primary Options for Colorectal Cancer Detection
The American Cancer Society updated colorectal cancer screening guidelines to include blood-based tests alongside colonoscopy and stool screening methods. The…
Submit Your Paper to GMJ
UK Reports Sharp Summer COVID-19 Rise as Hospitalizations Jump 24% in One Week
COVID-19 hospitalizations in England jumped 24% in one week during late June 2026, defying typical summer respiratory illness patterns. UK…
House cats’ cancer genetics reveal new treatment pathways for human breast cancer
A landmark study analyzing 495 cat tumors worldwide revealed 85% genetic similarity with human breast cancer. The research opens new…
Methionine Amino Acid Protects Against Fatal Inflammation in Preclinical Study
Salk Institute research shows methionine amino acid dramatically improved survival in mice with severe inflammatory conditions by enhancing kidney filtration…
Immune Drug Delays Rheumatoid Arthritis by Four Years After Treatment Ends
Clinical trial shows one year of abatacept treatment delayed rheumatoid arthritis onset by up to four years in high-risk individuals.…
UK Expands Prostate Cancer Screening Trial to Include More Black Men at Higher Risk
NHS England expands its Transform prostate cancer screening trial to better include black men, who face twice the risk of…
Syphilis Among Gay and Bisexual Men Falls to Decade Low in England
Syphilis diagnoses among gay and bisexual men in England have reached their lowest level in a decade, according to UK…
MHRA Grants Marketing Authorisations to 47 New Medicines in 2026
MHRA granted marketing authorisations to 47 new pharmaceutical products in 2026. The approvals reflect continued pharmaceutical innovation and UK regulatory…
New Pancreatic Cancer Drug Daraxonrasib Shows Promise in Phase 2 Trial
A phase 2 trial published in NEJM shows promise for daraxonrasib, a novel targeted therapy for previously treated metastatic pancreatic…